[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
July 16, 2003

Medical Illustrations on Display

JAMA. 2003;290(3):324. doi:10.1001/jama.290.3.324-a

The US Food and Drug Administration (FDA) has announced new regulations and internal reforms to streamline the approval of generic drugs.

The new rules limit drug companies to a single 30-month "stay" of a generic's entry into the market for resolution of a patent challenge. According to a 2002 Federal Trade Commission report, in at least six cases, pharmaceutical companies have blocked the development of generic equivalents of fast-selling drugs by pursuing multiple 30-month stays.

First Page Preview View Large
First page PDF preview
First page PDF preview
×